Lipid control in secondary prevention: Multicenter observational study in primary care;Control lipídico en prevención secundaria: Estudio multicéntrico, observacional en atención primaria

Atencion Primaria

Volumn 34, Issue 2, 2004, Pages 81-86

  Brotons, Carlos ^a   Maiques, A ^b   Mostazac, J ^c   Pinto X ^d   Vilaseca, J ^d  

^a EAP Sardenya   (Spain)

^b CS Manises   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Implementation; Primary care; Secondary prevention

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMMUNITY MEDICINE; DIASTOLIC BLOOD PRESSURE; DISEASE CONTROL; FAMILY MEDICINE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; MALE; MEDICAL SOCIETY; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; RISK REDUCTION; SECONDARY PREVENTION; SPAIN; STABLE ANGINA PECTORIS; STANDARD; SYSTOLIC BLOOD PRESSURE; UNSTABLE ANGINA PECTORIS;

EID: 3142678734     PISSN: 02126567     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0212-6567(04)79464-0     Document Type: Article

References (20)

1. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998;19:1434-503.
2. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomised controlled trials. JAMA 1999;282:2340-6.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-9.
4. Sacks F, Pleiffer M, Moye L, Rouleau J, Cole T. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol events. N Engl J Med 1996;335:1001-9.
5. The Long-term Intervention with Pravastatin in ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
6. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomised controlled trials. JAMA 1999;282:2340-6.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
8. Ministerio de Sanidad y Consumo, Sociedad Española de Cardiología y Sociedad Española de Arteriosclerosis. Control de la colesterolemia en España, 2000. Un instrumento para la prevención cardiovascular. Clin Invest Arteriosclerosis 2000;12:125-52.
9. Brady AJB, Oliver MA, Pittard JB. Secondary prevention in 24 431 patients with coronary heart disease: survey in primary care. BMJ 2001;322:1463.
10. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72.
11. Villar Álvarez F, Maiques Galán A, Brotons Cuixart C, Torcal Laguna J, Lorenzo Piqueras A, Vilaseca Canals J, et al. Prevención cardiovascular en atención primaria. Aten Primaria 2001; 28:13-27.
12. Grupo de Investigación del estudio PREMISE. Prevención secundaria del infarto de miocardio y calidad de vida relacionada con la salud. Med Clin (Barc) 2002;119:9-12.
13. Velasco JA, Cosín J, López Sendón JL, De Teresa E, De Oya M, Carrasco JL, et al. La prevención secundaria del infarto de miocardio en España. Estudio PREVESE. Rev Esp Cardiol 1997;50:406-15.
14. Brotons C, Calvo F, Cascant P, Ribera A, Moral I, Pernanyer-Miralda G. Is prophylactic treatment after myocardial infarction evidence-based? Fam Pract 1998;15:457-61.
15. De Oya M, López Sendón JL, De Teresa E, Velasco-Rami J, Villa E, Cosin J. The impact of landmark clinical trials on secondary prevention of acute myocardial infarction (AMI) in Spain: PREVESE 98 study [abstract]. Atherosclerosis 2000;151:107.
16. Grupo de Investigación del estudio ELIPSE. Prevención secundaria de la cardiopatía isquémica en la provincia de Ciudad Real. Efectividad de la terapéutica hipolipemiante en atención primaria. Med Clin (Barc) 2000;115:321-5.
17. Grupo PRESENCIAP. Estudio de prevención secundaria de la cardiopatía isquémica en la atención primaria (PRESENCIAP). Aten Prim 2001;27:29-32.
18. Campbell NC, Ritchie LD, Thain J, Deans HG, Rawles JM, Squair JL. Secondary prevention in coronary heart disease: a randomised trial of nurse led clinics in primary care. Heart 1998;80:447-52.
19. Jolly K, Bradley F, Sharp S, Smith H, Thompson S, Kinmonth A-L, et al, for the SHIP Collaborative group. Randomised controlled trial of follow up care in general practice of patients with myocardial infarction and angina: final results of the Southampton heart integrated care project (SHIP). BMJ 1999;318:706-11.
20. Moher M, Yudkin P, Wright L, Turner R, Fuller A, Schfield T, et al, for the Assessment of Implementation Strategies (ASSIST) Trial Collaborative Group. BMJ 2001;322:1-7.